Real‐world performance of the MiniMed™ 670G system in Europe
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the real‐world performance of the MiniMed 670G system in Europe, in individuals with diabetes. Materials and Methods: Data uploaded from October 2018 to July 2020 by individuals living in Europe were aggregated and retrospectively analysed. The mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR) and above (TAR) glycaemic ranges, system use and insulin consumed in users with 10 or more days of sensor glucose data after initial Auto Mode start were determined. Another analysis based on suboptimally (GMI > 8.0%) and well‐controlled (GMI < 7.0%) glycaemia pre‐Auto Mode initiation was also performed. Results: Users ( N = 14 899) spent a mean of 81.4% of the time in Auto Mode and achieved a mean GMI of 7.0% ± 0.4%, TIR of 72.0% ± 9.7%, TBR less than 3.9 mmol/L of 2.4% ± 2.1% and TAR more than 10 mmol/L of 25.7% ± 10%, after initiating Auto Mode. When compared with pre‐Auto Mode initiation, GMI was reduced by 0.3% ± 0.4% and TIR increased by 9.6% ± 9.9% ( P < .0001 for both). Significantly improved glycaemic control was observed irrespective of pre‐Auto Mode GMI levels of less than 7.0% or of more than 8.0%. While the total daily dose of insulin increased for both groups, a greater increase was observed in the latter, an increase primarily due to increased basal insulin delivery. By contrast, basal insulin decreased slightly in well‐controlled users. Conclusions: Most MiniMed 670G system users in Europe achieved TIR more than 70% and GMI less than 7% while minimizing hypoglycaemia, in a real‐world environment. These international consensus‐met outcomes were enabled by automated insulin delivery meeting real‐time insulin requirements adapted to each individual user.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“9 of less than 4% and an estimated HbA1c of less than 7%.(3) In addition, they are superior to the average glycaemia reported by several national registries,(6,7) and provide reassuring evidence for the efficacy of the system in a broader population.”
BackgroundSelf-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684 · cited 2×
“International and national guidelines have, accordingly, been updated to the near-physiological recommended goals of HbA1c less than 53 mmol/mol ( 7.0%), indicating a preference for lower HbA1c levels such as 48 mmol/mol (6.5%), provided it can be achieved safely.1,2 Additionally, professional societies have endorsed…”
BackgroundInfluentialThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“This is in contrast to non-automated insulin delivery, where insulin therapy increasing TIR or reducing mean glucose and reducing HbA1c is often associated with increased hypoglycaemia.(17,18) Longitudinal analysis of real-world outcomes showed a rapid beneficial effect with Auto Mode initiation that was apparent as e…”
BackgroundGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationHandelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2020-0490 · Cited by 248 · cited 1×
“5%), provided it can be achieved safely.(1,2) Additionally, professional societies have endorsed recommendations from an international consensus on durations of time spent in target glucose range,(3) as well as use of the calculated glucose management indicator (GMI), to approximate the levels of HbA1c.”
BackgroundRisk factors associated with severe hypoglycemia in older adults with type 1 diabetes
Weinstock, R. S., DuBose, S. N., Bergenstal, R. M., Chaytor, N. S., Peterson, C., Olson, B. A., Munshi, M. N., Perrin, A. J. S., Miller, K. M., Beck, R. W., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1426 · Cited by 171 · cited 1×
“Increased availability of continuous glucose monitoring (CGM) systems provided evidence that the relationship between hypoglycaemia occurrence and HbA1c is curvilinear, whereby increased hypoglycaemia can occur at high HbA1c levels, challenging the assumption that higher HbA1c negates hypoglycaemia.(11,12) Another cha…”
Background
Cited by
Carlson, A. L., Sherr, J. L., Shulman, D. I., Garg, S. K., Pop-Busui, R., Bode, B. W., Lilenquist, D. R., Brazg, R. L., Kaiserman, K. B., Kipnes, M. S., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0319 · Cited by 230
Self-citationISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Forlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
Garg, S. K., Grunberger, G., Weinstock, R., Lawson, M. L., Hirsch, I. B., DiMeglio, L. A., Pop-Busui, R., Philis-Tsimikas, A., Kipnes, M., Liljenquist, D. R., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0421 · Cited by 63
“Since then, real-world MiniMed 670G system use analyses of thousands living in the United States 17,18 and throughout Europe 19 have confirmed the findings from the pivotal trials and begun to highlight performance of the system in people with different levels of baseline glycemia.”
Self-citationReal-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
Metadata
- Authors
- Da Silva, J., Bosi, E., Jendle, J., Arrieta, A., Castaneda, J., Grossman, B., Cordero, T. L., Shin, J., & Cohen, O.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-05-27
- Volume
- 23
- Issue
- 8
- Pages
- 1942-1949
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3159211340
- Cited by
- 60
- References
- 8
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real‐world performance of the MiniMed™ 670G system in Europe. https://app.cochat.ai/papers/10.1111/dom.14424
- The paper
- Da Silva, J., Bosi, E., Jendle, J., Arrieta, A., Castaneda, J., Grossman, B., Cordero, T. L., Shin, J., & Cohen, O. (2021). Real‐world performance of the MiniMed™ 670G system in Europe. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.